Work

Assessing impact of RDI on outcomes in patients treated with enfortumab vedotin-pembrolizumab combination therapy.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.7_suppl.689

Authors: Lucas Antonio Viti-Guzman, Jordan Fredette, Joy Li, Nagendra Dhanikonda, Miraan Jhaveri, Jasmeet Kaur, Hal Rives, Aangi Shah, Fern Anari, Daniel M. Geynisman, Elizabeth R. Plimack, Pooja Ghatalia, Matthew R. Zibelman

Institutions: Temple University, Fox Chase Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7133230277

Cites:

Cited by:

Related to: